Status:

COMPLETED

The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis

Lead Sponsor:

Aljazeera Hospital

Conditions:

Infertility

Autoimmune Thyroiditis

Eligibility:

FEMALE

18-35 years

Phase:

PHASE2

Brief Summary

The aim of the work is to determine whether the use of immunomodulatory drugs could improve the reproductive of outcome of infertile patients who have autoimmune thyroiditis with positive autoimmune a...

Eligibility Criteria

Inclusion

  • Infertility patients who have autoimmune thyroiditis With positive autoimmune thyroiditis and TSH level above 2 IU.

Exclusion

  • All patients who have other autoimmune diseases especially antiphospholipid syndrome, hepatitis c viral disease.
  • Patients who have any medical disorders ( eg. D.M. HTN .Epilepsy ….)

Key Trial Info

Start Date :

March 7 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 20 2024

Estimated Enrollment :

194 Patients enrolled

Trial Details

Trial ID

NCT03289403

Start Date

March 7 2018

End Date

January 20 2024

Last Update

December 27 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Aljazeera (Al Gazeera) hospital

Giza, Egypt

The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis | DecenTrialz